Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 227

The DOI matches its Crossref record.

Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients

Open access
Suzuki, Shigeaki, Nishikawa, Atsuko, Kuwana, Masataka, Nishimura, Hiroaki, Watanabe, Yurika, Nakahara, Jin, Hayashi, Yukiko K., Suzuki, Norihiro, Nishino, Ichizo·2015·Orphanet Journal of Rare Diseases

Abstract

BACKGROUND: Anti-signal recognition particle (SRP) antibodies are used as serological markers of necrotizing myopathy, which is characterized by many necrotic and regenerative muscle fibers without or with minimal inflammatory cell infiltration. The clinical spectrum associated with anti-SRP antibodies seems to be broad. OBJECTIVE: To describe the clinical characteristics, autoantibodies status, and neurological outcome associated with anti-SRP antibody. METHODS: We studied clinical and laboratory findings of 100 patients with inflammatory myopathy and anti-SRP antibodies. Anti-SRP antibodies in serum were detected by the presence of 7S RNA using RNA immunoprecipitation. In addition, enzyme-linked immunosorbent assays (ELISAs) using a 54-kD protein of SRP (SRP54) and 3-hydroxyl-3-methylglutatyl-coenzyme A reductase (HMGCR) were also conducted. RESULTS: The mean onset age of the 61 female and 39 male patients was 51 years (range 4-82 years); duration ≥ 12 months before diagnosis was seen in 23 cases. All patients presented limbs weakness; 63 had severe weakness, 70 neck weakness, 41 dysphagia, and 66 muscle atrophy. Extramuscular symptoms and associated disorders were infrequent. Creatine kinase levels were mostly more than 1000 IU/L. Histological diagnosis showed 84 patients had necrotizing myopathy, and apparent cell infiltration was observed in 16 patients. Anti-SRP54 antibodies were undetectable in 18 serum samples with autoantibodies to 7S RNA. Anti-HMGCR antibodies were positive in 3 patients without the statin treatment, however, were negative in 5 patients with statin-exposure at disease onset. All but 3 patients were treated by corticosteroids and 62 (77 %) of these 81 patients required additional immunotherapy. After 2-years treatment, 22 (27 %) of these 81 patients had poor neurological outcomes with modified Rankin scale scores of 3-5. Multivariate analysis revealed that pediatric disease onset was associated with the poor outcomes. CONCLUSION: Anti-SRP antibodies are associated with different clinical courses and histological presentations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13023-015-0277-y

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 227

Metadata

Authors
Suzuki, S., Nishikawa, A., Kuwana, M., Nishimura, H., Watanabe, Y., Nakahara, J., Hayashi, Y. K., Suzuki, N., & Nishino, I.
Venue
Orphanet Journal of Rare Diseases
Published
2015-05-13
Volume
10
Issue
1
Pages
61-61
ISSN
1750-1172 (ISSN-L)
OpenAlex
W2134758619
Cited by
227
References
0
FWCI
14.22
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. https://app.cochat.ai/papers/10.1186/s13023-015-0277-y
The paper
Suzuki, S., Nishikawa, A., Kuwana, M., Nishimura, H., Watanabe, Y., Nakahara, J., Hayashi, Y. K., Suzuki, N., & Nishino, I. (2015). Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-015-0277-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.